Home » Topics » Regulatory » EMA

EMA
RSS

Novartis withdraws MAA for pre-pandemic vaccine Aflunov

June 18, 2008

CHMP recommends refusing Takeda's MAA for ramelteon

June 9, 2008

Positive opinion issued to broaden use of Erbitux, including first-line colorectal cancer

June 9, 2008

CHMP issues positive opinion for antibacterial agent Doribax

June 6, 2008

CHMP issues positive opinion for icatibant in HAE; FDA issues not approvable letter

April 28, 2008

GSK receives CHMP positive opinion for Volibris

Feb. 25, 2008

EMEA recommends that new warnings be included in product information for Novartis' Sebivo

Feb. 19, 2008

Lenalidomide approved in Australia and Canada, receives negative opinion in Europe

Jan. 29, 2008

EMEA issues opinion on safety of Gardasil

Jan. 29, 2008

EMEA recommends approval of novel oral anticoagulant, Pradaxa

Jan. 28, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...